Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection
Microbiome-Sparing Action of Ridinilazole associated with Superiority over Vancomycin in Sustained Clinical Response Rate OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and …